SCHEMBL6318489

SCHEMBL6318489

CCOC(=O)N1CCC(NC(=O)c2c(-c3coc4ccccc34)noc2N)CC1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.47
HSD17B10 Q99714 4/20 0.47
ALDH1A1 P00352 6/20 0.47
HPGD P15428 2/20 0.47
MAPK1 P28482 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
RAB9A P51151 1/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TP53 P04637 2/20 0.44
GAA P10253 2/20 0.43
CCR8 P51685 1/20 0.43
LMNA P02545 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320666 0.84 MAOB (0.49) KDM4EHSD17B10ALDH1A1HPGDMAPK1
SCHEMBL6316445 0.84 MAOB (0.52) KDM4EHSD17B10ALDH1A1HPGDMAPK1
SCHEMBL6318543 0.83 MAOB (0.60) L3MBTL1
SCHEMBL6322682 0.83 MAOB (0.54) KDM4EALDH1A1HPGDSMN1; SMN2RAB9A
SCHEMBL6325219 0.83 MAOB (0.54) KDM4EALDH1A1HPGDSMN1; SMN2RAB9A
SCHEMBL6314930 0.81 ALDH1A1 (0.50) KDM4EHSD17B10ALDH1A1HPGDMAPK1
SCHEMBL6317233 0.81 NOS2 (0.54) KDM4EHSD17B10ALDH1A1HPGDMAPK1
SCHEMBL6316229 0.79 LMNA (0.46) KDM4EHSD17B10ALDH1A1HPGDMAPK1
SCHEMBL6316279 0.78 ALDH1A1 (0.49) KDM4EHSD17B10ALDH1A1HPGDMAPK1
SCHEMBL6316531 0.77 CA1 (0.46) KDM4EHSD17B10ALDH1A1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 KDM4E 1382/4885HSD17B10 4152/4885ALDH1A1 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.